Biogen (BIIB) announced that the US FDA has granted Breakthrough Therapy Designation for litifilimab for the treatment of cutaneous lupus erythematosus.

Biogen's receipt of Breakthrough Therapy Designation from the FDA for litifilimab represents a significant advancement in their pipeline.

Newsquawk StaffPublished On the live feed at 1 more headline followed before this page went public
Newsquawk headlinesUTC

US PRE-MARKET MOVERS: MSFT/META/TSLA, NVDA, AMZN, AI, AMAT, RGNX, STX, TXN, ASML, SBUX, T, PPG, ELV, QRVO

Starbucks (SBUX) Q1 2026 (USD): Adj. EPS 0.56 (exp. 0.59), Revenue 9.9bln (exp. 9.65bln); comp sales +4% (exp. 1.88%)

Biogen (BIIB) announced that the US FDA has granted Breakthrough Therapy Designation for litifilimab for the treatment of cutaneous lupus erythematosus.

The question of Putin-Zelensky meeting was raised several times in Putin-Trump call, according to reports; Kremlin said Trump suggested they consider such possibility, and are not refusing contacts

[MARKET UPDATE] Crude futures quickly rise and pare gains, while equities quickly fall and pare losses after US President Trump reiterated that an armada was heading to Iran

Open the platform and use it. The whole workspace is free to try, with no signup and no card. When you want the headlines arriving live instead of on a delay, Newsquawk Pro is £24.99 for 7 days.

Free. No signup, no card.
Context

This designation is typically viewed positively as it can expedite the development and approval process, potentially enhancing Biogen's competitive positioning in the dermatological space. Investors will likely assess how this news impacts the company's market valuation and future earnings outlook, especially given the focus on biotech innovation.

Related headlines

The whole workspace, free to try.

Try it free